Professor Charlotte Teunissen summarises research presented at ADPD 2024™ about alzheimer's biomarkers, a novel assay for multiphosphorylated tau and the impact of confounding factors.
Professor Oskar Hansson summarises sessions from ADPD 2024™ on anti-amyloid immunotherapies
Professor Lea Grinberg explains research on how Alzheimer's Disease is linked to sleep disturbance, and whether interventions for bad sleep can stop tiredness as a risk factor.
Professor Zvezdan Pirtošek comments on a session about whether lecanemab treatment should extend beyond 18 months.
Rik Ossenkoppele discusses the latest research presented on blood-based biomarkers, including their accuracy for diagnosing Alzheimer’s disease and when best to use them.
Michelle Mielke discusses the current status for blood-based biomarker use in primary care in light of research presented at AAIC24.
Petrice Cogswell summarizes research looking at temporal modelling of blood-based biomarkers and when to use them to predict brain amyloid deposition.
Episode 8: Juan Fortea comments on future opportunities for anti-amyloid antibody treament given the consolidation of clinical trial data in the real world
Episode 9: Claire Paquet discusses the implications of the real-world and recommendation data presented on anti-amyloid antibody therapies for AD
Kris Kowdley and David Jones share their insights on the evolving landscape of Primary Biliary Cholangitis (PBC), including new and upcoming therapy options, and how these may change practice for the disease
David Jones meets with patient and patient advocate Mo Christie as they discuss the patient experience for PBC, including the burden of the disease and its impact on quality of life, with special reference to the common, and commonly misunderstood symptom, itch.
Kris Kowdley meets with patient Sabrina Reeser as they discuss the patient experience of treatment for PBC, including treatment challenges, variability in doctor-patient communication and involvement in clinical trials.
Dr. Rozalina McCoy discusses breaking news and clinical implications of data presented at the ATTD 2024 conference on CGM technology.
Dr. Eugene Wright, Jr. discusses breaking news and clinical implications of data presented at the ADA 2024 conference on CGM technology.
Dr. Jennifer Green discusses breaking news and clinical implications of data presented at EASD 2024 on CGM technology use in type 2 diabetes.
Dr. Jennifer Green shares exciting CGM device highlights from the 2025 Standards of Care in Diabetes revision by the ADA.
Dr. Jamie L. Schneider, delves into the practical considerations for targeted therapy in ALK-rearranged non-small cell lung cancer (NSCLC) through an engaging patient case commentary.
Dr. Lizza Hendriks explores a complex case involving a 40-year-old male with ALK-rearranged non-small cell lung cancer (NSCLC).
Dr. Solange Peters shares invaluable insights into the management of ALK-positive NSCLC with a special focus on adjuvant therapy.
Listen to Professor Tina Vilsbøll provide an overview of diabetic kidney disease (DKD) and the diabetes-cardio-kidney spectrum, as she discusses the importance of proactive identification and management.